The FDA approved Ozempic (semaglutide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
Retatrutide (LY3437943) is a triple receptor agonist activating GIP, GLP-1, and glucagon receptors
Tips to Keep Advancing Your Results: Increase intensity by increasing duration, resistance (weight), or adding new exercises
Sotagliflozin in patients with diabetes and chronic kidney disease
People want treatments that are effective, non-invasive, and low maintenance
Side Effect Management: While many people tolerate GLP-1s well, side effects like nausea or fatigue can occur, especially at the beginning